Edition:
India

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

52.50USD
12 Dec 2017
Change (% chg)

$-0.81 (-1.52%)
Prev Close
$53.31
Open
$53.19
Day's High
$53.67
Day's Low
$52.29
Volume
16,629
Avg. Vol
32,140
52-wk High
$60.28
52-wk Low
$41.64

Chart for

About

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $872.76
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

26 Oct 2017

BRIEF-Anika announces forthcoming appointment of Thomas Finnerty as chief human resources officer

* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Anika Therapeutics announces regulatory approval for Monovisc® in Australia

* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints

17 Oct 2017

BRIEF-Kayne Anderson Rudnick Investment Management Llc reports 11.49 pct passive stake in Anika Therapeutics Inc as of August 08, 2017 - SEC filing

* Kayne anderson rudnick investment management llc reports 11.49 percent passive stake in anika therapeutics inc as of august 08, 2017 - sec filing Source text - (http://bit.ly/2fqZxZ8) Further company coverage:

09 Aug 2017

BRIEF-Anika announces appointment of Joseph Darling as president

* Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo Source text for Eikon: Further company coverage:

27 Jul 2017

BRIEF-Anika announces regulatory approval for Monovisc in India

* Anika announces regulatory approval for Monovisc in India for the treatment of pain associated with osteoarthritis of all synovial joints Source text for Eikon: Further company coverage:

25 Jul 2017

BRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc

* Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc

18 Jul 2017

Competitors

Earnings vs. Estimates